SCHEMBL3169999

SCHEMBL3169999

[Li]Cc1ccncc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451396 0.75
SCHEMBL151822 0.73 LOXL2 (0.68)
SCHEMBL721736 0.73 CYP17A1 (0.61)
Ammonia Solution, Strong SCHEMBL9306930 0.71 LOXL2 (0.65)
Water SCHEMBL31124596 0.71 LOXL2 (0.65)
Water SCHEMBL31124597 0.71 LOXL2 (0.65)
SCHEMBL13873567 0.71 CYP17A1 (0.65)
Hydrochloric Acid SCHEMBL11103093 0.69
SCHEMBL42462 0.69
SCHEMBL726645 0.69 HRH1 (0.73)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-20130143928-A1 BIS-PYRINIDIUM COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2013-06-06 US disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
US-20100016367-A1 BIS-PYRINIDIUM COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2010-01-21 US disclosed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP disclosed
EP-2016069-A1 BIS-PYRIDINIUM COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2009-01-21 EP disclosed
US-20080200679-A1 Alpha-HYDROXY, alpha-SUBSTITUTED METHYLENEBISPHOSPHONATES AND PHOSPHONOACETATES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2008-08-21 US disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed
WO-2007128059-A1 BIS-PYRIDINIUM COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2007-11-15 WO disclosed
EP-0738714-A2 Process for preparing new fibrinogen receptor antagonists MERCK &amp; CO. INC. (US) 1996-10-23 EP disclosed
CN-1076441-A The method for preparing fibrinogen deceptor antagonists MERCK & CO INC (US) 1993-09-22 CN disclosed
WO-1993016995-A1 PROCESS FOR PREPARING FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1993-09-02 WO disclosed
EP-0558139-A1 Process for preparing fibrinogen receptor antagonists MERCK & CO. INC. (US) 1993-09-01 EP disclosed
US-5206373-A Process for preparing fibrinogen receptor antagonists MERCK & CO., INC. (US) 1993-04-27 US disclosed
EP-0428849-A2 Retroviral protease inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-29 EP disclosed
US-4499287-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1985-02-12 US disclosed
US-4456761-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1984-06-26 US disclosed
US-4356182-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-10-26 US disclosed
US-4291040-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1981-09-22 US disclosed